VRTX

Vertex Pharmaceuticals Incorporated (VRTX)

Last Price$488.3(2.3%)
Market Cap$124.8B

VRTX Rating

VRTX Intrinsic Value

Key Highlights:
As of Mar 11, 2025 VRTX Relative Value is $186.1, which is overvalued by 61.9%, compared to current share price of $488.3.
As of Mar 11, 2025 VRTX DCF Value is N/A, which is undervalued by N/A, compared to current share price of $488.3.
Methodology
Price per share, $
Current share price
488.3
DCF value
not available

VRTX Share Price History

1W 0.4%
1M 7.3%
6M 2.9%
YTD 18.8%
1Y 17.8%
3Y 106.5%
5Y 121.6%
10Y 298.2%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!

VRTX Stock Metrics

Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$124.8B
Shares Outstanding
256M
Employees
94K
Valuation (LTM)
(488.1x)
(157.9x)
(233.1x)
7.6x
0.2x
(0.6%)
Return on Capital
(3.3%)
(2.4%)
(15.0%)
(5.5%)
Earnings

VRTX Stock Financials

VRTX Income Statement Metrics

Annual
Quarterly
LTM

Revenue

$11.0B +11.7% YoY

Operating Income

($0.2B) N/A

Net Income

($0.5B) N/A

VRTX Cash Flow Statement Metrics

Annual
Quarterly
LTM

Operating Cash Flow (OCF)

($492.6M) N/A YoY

Capital Expenditure (CAPEX)

($297.7M) +15.2% YoY

Free Cash Flow (FCF)

($790.3M) N/A YoY

VRTX Income Statement Overview

Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$11.0B 11.7% YoY
$9,489.6M 10.3% YoY
86.1% margin
Cost of revenue
$1,530.5M 21.3% YoY
Operating expenses
$9,722.5M 103.6% YoY
Net income
$535.6M 0.0% YoY
(4.9%) margin
Other: $4,092.3M
R&D
$3,630.3M 14.8% YoY
32.9% of revenue
SG&A
$1,464.3M 28.8% YoY
13.3% of revenue

VRTX Balance Sheet Overview

Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$22.5B
Current assets ($9,596.4M, 42.6% of total)
$6,115.9M (27.1%)
$1,609.4M (7.1%)
Other current assets
$1,871.1M (8.3%)
Non-current assets ($12.9B, 57.4% of total)
$5,107.9M (22.7%)
$825.9M (3.7%)
Other non-current assets
$4,418.4M (19.6%)
Financial position
($4,366.4M)
$6,115.9M$1,749.5M
Cash & Short-term Investments
Total Debt

VRTX Stock Ratios

VRTX Earnings Surprises

Crunching data... Almost there!

VRTX Dividends

VRTX Dividend Yield

Crunching data... Almost there!

VRTX Dividend Per Share

Competing with VRTX

Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name
Market Cap
Quality rating
Intrinsic value
1Y Return
Revenue
Free Cash Flow
Revenue growth
FCF margin
Gross margin
ROIC
Total Debt to Equity
$124.8B
5.7
$187.5
61.6% overvalued
17.8%
$11.0B
($790.3M)
11.5%
(7.2%)
86.1%
(15.0%)
10.7%
$77.0B
6.3
$1,048.3
46.0% undervalued
(25.4%)
$14.2B
$3,597.2M
8.3%
25.3%
84.5%
25.7%
5.7%
$34.4B
5.8
$123.0
78.8% overvalued
50.8%
$2,258.9M
($211.2M)
127.3%
(9.4%)
86.8%
(41.3%)
N/A
$30.7B
5.2
$91.8
61.6% overvalued
60.1%
$2,248.2M
($42.6M)
23.0%
(1.9%)
85.6%
(7.2%)
1,931.9%
$24.0B
5.9
$191.1
94.2% undervalued
2.2%
€2,751.1M
(€229.8M)
(28.0%)
(8.4%)
80.3%
(37.8%)
1.3%
$14.5B
5.4
$71.6
120.5% undervalued
11.2%
$2,263.9M
$2,769.0M
(3.8%)
122.3%
73.9%
14.5%
73.6%
$14.2B
5.6
$42.2
38.1% overvalued
12.0%
$4,241.2M
$235.2M
14.8%
5.5%
92.3%
(12.7%)
1.3%
$13.8B
7.7
$542.2
78.1% undervalued
22.0%
$2,877.4M
$1,080.6M
23.6%
37.6%
89.2%
65.4%
4.7%
$13.4B
6.7
$46.9
33.5% overvalued
(18.0%)
$2,850.5M
$475.4M
17.8%
16.7%
78.6%
11.0%
10.7%
$13.3B
5.9
$0.6
96.9% overvalued
330.2%
$0.0
($142.1M)
N/A
N/A
N/A
(3,335.4%)
1.9%
$1,846.9M
5.5
$2,745.6
1,111.0% undervalued
39.9%
$3,316.8M
($1,041.0M)
50.5%
(31.4%)
83.7%
(43.2%)
32.1%

FAQ

What is Vertex Pharmaceuticals Incorporated (VRTX) stock rating?

As of today, Vertex Pharmaceuticals Incorporated has a stock rating of 6 (out of 10), which is considered Good.

is Vertex Pharmaceuticals Incorporated (VRTX) a good stock to buy?

As of today, Vertex Pharmaceuticals Incorporated has a Good stock rating, which is 61.6% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.